Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genetics and Genomics

A liquid biopsy signature for predicting early recurrence in patients with gastric cancer

British Journal of Cancer volume 128, pages 1105–1116 (2023)Cite this article

Subjects

Abstract

Background

Gastric cancer (GC) patients who experience recurrence within the first year following surgery (early recurrence [ER]) exhibit worse prognosis. Herein, we established a microRNA-based liquid biopsy assay to predict ER in GC patients.

Methods

A comprehensive biomarker discovery was performed by analysing miRNA expression profiling in 271 primary GC tumours. Thereafter, the expression of these biomarkers was validated in 290 GC cases, which included 218 tissues and 72 pre-treatment sera, from two independent institutions.

Results

A panel of 8 miRNAs was identified during the initial biomarker discovery, and this panel could robustly predict ER in a tissue-based clinical cohort (area under the curve [AUC]: 0.81). Furthermore, a model combining the miRNA panel, microsatellite instability (MSI) status and tumour size exhibited superior predictive performance (AUC: 0.86), and was defined as a Prediction of Early Recurrence in GC (PERGC) signature, which was successfully validated in another independent cohort (AUC: 0.82). Finally, the PERGC signature was translated into a liquid biopsy assay (AUC: 0.81), and a multivariate regression analysis revealed this signature to be an independent predictor for ER (odds ratio: 11.20).

Conclusion

We successfully established a miRNA-based liquid biopsy signature that robustly predicts the risk of ER in GC patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival outcomes of stage II/III gastric cancer patients with early recurrence in two independent public data sets.
Fig. 2: Biomarker discovery phase of candidate miRNAs to predict early recurrence in primary tumours from gastric cancer patients.
Fig. 3: Clinical training phase of the PERGC signature for predicting the early recurrence in tissue specimens from stage II/III GC patients.
Fig. 4: Clinical validation phase for the PERGC signature in predicting early recurrence in tissue specimens from stage II/III GC patients.
Fig. 5: Clinical performance evaluation phase for the PERGC model as a liquid biopsy assay for predicting early recurrence in pre-surgery serum specimens from stage II/III GC patients.

Data availability

The data sets analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020;159:335.e15–49.e15.

    Article  Google Scholar 

  3. Alnoor M, Boys JA, Worrell SG, Oh DS, Hagen JA, DeMeester SR. Timing and pattern of recurrence after gastrectomy for adenocarcinoma. Am Surg. 2015;81:1057–60.

    Article  PubMed  Google Scholar 

  4. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219:664–75.

    Article  PubMed  Google Scholar 

  5. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.

    Article  CAS  PubMed  Google Scholar 

  6. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

    Article  CAS  PubMed  Google Scholar 

  8. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388–98.

    Article  PubMed  Google Scholar 

  9. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer. 2018;21:144–54.

    Article  PubMed  Google Scholar 

  10. Chiang CY, Huang KH, Fang WL, Wu CW, Chen JH, Lo SS, et al. Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma. World J Surg. 2011;35:2472–8.

    Article  PubMed  Google Scholar 

  11. Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18.

    Article  CAS  PubMed  Google Scholar 

  13. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.

    Article  PubMed  Google Scholar 

  14. Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–8.

    Article  CAS  PubMed  Google Scholar 

  15. Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, et al. Development and validation of a six-gene recurrence risk score assay for gastric cancer. Clin Cancer Res. 2016;22:6228–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Motoori M, Takemasa I, Yano M, Saito S, Miyata H, Takiguchi S, et al. Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. Int J Cancer. 2005;114:963–8.

    Article  CAS  PubMed  Google Scholar 

  18. Yan Z, Xiong Y, Xu W, Li M, Cheng Y, Chen F, et al. Identification of recurrence-related genes by integrating microRNA and gene expression profiling of gastric cancer. Int J Oncol. 2012;41:2166–74.

    Article  CAS  PubMed  Google Scholar 

  19. Liu X, Zhang X, Zhang Z, Chang J, Wang Z, Wu Z, et al. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 2017;141:2093–102.

    Article  CAS  PubMed  Google Scholar 

  20. Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z, et al. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12:2072–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhang Y, Li J, Yu J, Liu H, Shen Z, Ye G, et al. Circular RNAs signature predicts the early recurrence of stage III gastric cancer after radical surgery. Oncotarget. 2017;8:22936–43.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, et al. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 2016;19:744–53.

    Article  CAS  PubMed  Google Scholar 

  23. Goel A. Somatostatin methylation as a biomarker for gastric cancer: ready for “prime time” or for further validation? Dig Dis Sci. 2011;56:1–3.

    Article  PubMed  Google Scholar 

  24. Okugawa Y, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35:2731–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 2014;455:43–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lee IS, Lee H, Hur H, Kanda M, Yook JH, Kim BS, et al. Transcriptomic profiling identifies a risk stratification signature for predicting peritoneal recurrence and micrometastasis in gastric cancer. Clin Cancer Res. 2021;27:2292–300.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lee IS, Sahu D, Hur H, Yook JH, Kim BS, Goel A. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer. Gastric Cancer. 2021;24:655–65.

    Article  CAS  PubMed  Google Scholar 

  28. Woo Y, Behrendt CE, Yang A, Hahn M, Goel A, Li H, et al. Tumor epigenetic signature and survival in resected gastric cancer patients. J Am Coll Surg. 2021;232:483.e1–91.e1.

    Article  Google Scholar 

  29. Roy S, Kanda M, Nomura S, Zhu Z, Toiyama Y, Taketomi A, et al. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Mol Cancer. 2022;21:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee IS, Zhu Z, Lee J, Park JO, Wu X, Ong T, et al. A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. Mol Cancer. 2022;21:9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Shimura T, Kandimalla R, Okugawa Y, Ohi M, Toiyama Y, He C, et al. Novel evidence for m(6)A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer. Br J Cancer. 2022;126:228–37.

    Article  CAS  PubMed  Google Scholar 

  32. Aurello P, Petrucciani N, Antolino L, Giulitti D, D’Angelo F, Ramacciato G. Follow-up after curative resection for gastric cancer: Is it time to tailor it? World J Gastroenterol. 2017;23:3379–87.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Diniz TP, da Costa WL Jr, Gomes CC, de Jesus VHF, Felismino TC, Torres SM, et al. Symptomatic recurrence and survival outcomes after curative treatment of gastric cancer: does intensive follow-up evaluation improve survival? Ann Surg Oncol. 2022;29:274–84.

    Article  PubMed  Google Scholar 

  34. Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–7.

    Article  CAS  PubMed  Google Scholar 

  35. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Shigeyasu K, Nagasaka T, Mori Y, Yokomichi N, Kawai T, Fuji T, et al. Clinical significance of MLH1 methylation and CpG island methylator phenotype as prognostic markers in patients with gastric cancer. PLoS ONE. 2015;10:e0130409.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Shigeyasu K, Toden S, Zumwalt TJ, Okugawa Y, Goel A. Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers. Clin Cancer Res. 2017;23:2391–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111–30.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer. Cancer Res Treat. 2020;52:1178–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–400.

    Article  PubMed  Google Scholar 

  42. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.

    Article  CAS  PubMed  Google Scholar 

  43. Kuhn M. Building predictive models in R using the caret package. J Stat Softw. 2008;28:1–26.

    Article  Google Scholar 

  44. Mevik BH, Wehrens R. The pls package: principal component and partial least squares regression in R. J Stat Softw. 2007;18:1–23.

    Article  Google Scholar 

  45. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.

  47. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  48. Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, et al. A microRNA signature identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases. Gastroenterology 2020;159:562–74.

    Article  CAS  PubMed  Google Scholar 

  49. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS ONE. 2010;5:e9393.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Ashktorab H, Smoot DT, Farzanmehr H, Fidelia-Lambert M, Momen B, Hylind L, et al. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer. 2005;116:914–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  52. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.

    Article  CAS  PubMed  Google Scholar 

  53. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer. 2018;18:449.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127–31.

    Article  CAS  PubMed  Google Scholar 

  56. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20:18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216–21.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

    Article  PubMed  Google Scholar 

  59. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Kota Nakamura, Dr. Katsuki Miyazaki, Dr. Silei Sui, Dr. Caiming Xu, Dr. Hiroyuki Hanayama, Dr. Milad Moloudizargari and Dr. Nour-Lynn Mouallem for their thoughtful discussions and advice during the course of this project.

Funding

This work was supported by the CA072851, CA181572, and CA187956 grants from the National Cancer Institute, National Institutes of Health, and a generous pilot grant from the Stupid Strong Foundation.

Author information

Authors and Affiliations

  1. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, CA, USA

    Keisuke Okuno, Souvick Roy & Ajay Goel

  2. Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan

    Keisuke Okuno, Masanori Tokunaga & Yusuke Kinugasa

  3. Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan

    Shuichi Watanabe

  4. Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Mitsuro Kanda & Yasuhiro Kodera

  5. City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Ajay Goel

Authors
  1. Keisuke Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuichi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Souvick Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuro Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masanori Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhiro Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yusuke Kinugasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ajay Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design (KO, SW, MT, Y Kinugasa, AG); provision of samples (KO, MK, MT, Y Kodera, Y Kinugasa); acquisition of clinical data (KO, MK, MT, Y Kodera, Y Kinugasa, AG); analysis and interpretation of data (KO, SW, SR, AG); statistical analysis (KO, SW, SR, AG); drafting of the manuscript (KO, SW, SR, MK, MT, Y Kodera, Y Kinugasa, AG).

Corresponding author

Correspondence to Ajay Goel.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

A written informed consent was obtained from all patients who enrolled at the present study. The study was conducted in compliance with the Declaration of Helsinki and was approved by the Institutional Review Boards of all participating institutions.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okuno, K., Watanabe, S., Roy, S. et al. A liquid biopsy signature for predicting early recurrence in patients with gastric cancer. Br J Cancer 128, 1105–1116 (2023). https://doi.org/10.1038/s41416-022-02138-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-02138-1

Search

Advanced search

Quick links